

Atorvastatin Formulation

Version Revision Date: SDS Number: Date of last issue: 04/24/2019
6.1 09/13/2019 184708-00009 Date of first issue: 06/17/2015

SECTION 1. IDENTIFICATION

Product name : Atorvastatin Formulation

Manufacturer or supplier's details

Company name of supplier : Merck & Co., Inc
Address : 2000 Galloping Hill Road
 Kenilworth - New Jersey - U.S.A. 07033
Telephone : 908-740-4000
Telefax : 908-735-1496
Emergency telephone : 1-908-423-6000
E-mail address : EHSDATASTEWARD@merck.com

Recommended use of the chemical and restrictions on use

Recommended use : Pharmaceutical

SECTION 2. HAZARDS IDENTIFICATION**GHS classification in accordance with 29 CFR 1910.1200**

Combustible dust

Specific target organ toxicity : Category 2 (Liver, muscle)
- repeated exposure (Oral)

GHS label elements

Hazard pictograms :



Signal Word : Warning

Hazard Statements : If small particles are generated during further processing, handling or by other means, may form combustible dust concentrations in air.
H373 May cause damage to organs (Liver, muscle) through prolonged or repeated exposure if swallowed.

Precautionary Statements : **Prevention:**
P260 Do not breathe dust.
Response:
P314 Get medical advice/ attention if you feel unwell.
Disposal:
P501 Dispose of contents/ container to an approved waste disposal plant.

Other hazards

Dust contact with the eyes can lead to mechanical irritation.
Contact with dust can cause mechanical irritation or drying of the skin.

Atorvastatin Formulation

Version Revision Date: SDS Number: Date of last issue: 04/24/2019
6.1 09/13/2019 184708-00009 Date of first issue: 06/17/2015

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

Chemical name	CAS-No.	Concentration (% w/w)
Calcium carbonate	471-34-1	>= 30 - < 50
Cellulose	9004-34-6	>= 20 - < 30
Atorvastatin	134523-03-8	>= 10 - < 20

Actual concentration is withheld as a trade secret

SECTION 4. FIRST AID MEASURES

General advice : In the case of accident or if you feel unwell, seek medical advice immediately.
When symptoms persist or in all cases of doubt seek medical advice.

If inhaled : If inhaled, remove to fresh air.
Get medical attention if symptoms occur.

In case of skin contact : Wash with water and soap.
Get medical attention if symptoms occur.

In case of eye contact : If in eyes, rinse well with water.
Get medical attention if irritation develops and persists.

If swallowed : If swallowed, DO NOT induce vomiting.
Get medical attention if symptoms occur.
Rinse mouth thoroughly with water.

Most important symptoms and effects, both acute and delayed : May cause damage to organs through prolonged or repeated exposure if swallowed.
Contact with dust can cause mechanical irritation or drying of the skin.
Dust contact with the eyes can lead to mechanical irritation.

Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Notes to physician : Treat symptomatically and supportively.

SECTION 5. FIRE-FIGHTING MEASURES

Suitable extinguishing media : Water spray
Alcohol-resistant foam
Carbon dioxide (CO₂)
Dry chemical

Unsuitable extinguishing media : None known.

Specific hazards during fire fighting : Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard.
Exposure to combustion products may be a hazard to health.

Hazardous combustion products : Carbon oxides
Nitrogen oxides (NO_x)
Fluorine compounds
Metal oxides

Atorvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/24/2019
6.1	09/13/2019	184708-00009	Date of first issue: 06/17/2015

Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Use water spray to cool unopened containers.
Remove undamaged containers from fire area if it is safe to do so.
Evacuate area.

Special protective equipment for fire-fighters : In the event of fire, wear self-contained breathing apparatus.
Use personal protective equipment.

SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures : Use personal protective equipment.
Follow safe handling advice and personal protective equipment recommendations.

Environmental precautions : Discharge into the environment must be avoided.
Prevent further leakage or spillage if safe to do so.
Retain and dispose of contaminated wash water.
Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up : Sweep up or vacuum up spillage and collect in suitable container for disposal.
Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).
Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration.
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

SECTION 7. HANDLING AND STORAGE

Technical measures : Static electricity may accumulate and ignite suspended dust causing an explosion.
Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.

Local/Total ventilation : Use only with adequate ventilation.

Advice on safe handling : Do not breathe dust.
Do not swallow.
Avoid contact with eyes.
Avoid prolonged or repeated contact with skin.
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment
Minimize dust generation and accumulation.
Keep container closed when not in use.
Keep away from heat and sources of ignition.
Take precautionary measures against static discharges.

Atorvastatin Formulation

Version 6.1 Revision Date: 09/13/2019 SDS Number: 184708-00009 Date of last issue: 04/24/2019
 Date of first issue: 06/17/2015

Take care to prevent spills, waste and minimize release to the environment.

Conditions for safe storage : Keep in properly labeled containers.
 Store in accordance with the particular national regulations.

Materials to avoid : Do not store with the following product types:
 Strong oxidizing agents

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Ingredients with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Calcium carbonate	471-34-1	TWA (Respirable)	5 mg/m ³ (Calcium carbonate)	NIOSH REL
		TWA (total)	10 mg/m ³ (Calcium carbonate)	NIOSH REL
Cellulose	9004-34-6	TWA	10 mg/m ³	ACGIH
		TWA (Respirable)	5 mg/m ³	NIOSH REL
		TWA (total)	10 mg/m ³	NIOSH REL
		TWA (total dust)	15 mg/m ³	OSHA Z-1
		TWA (respirable fraction)	5 mg/m ³	OSHA Z-1
Atorvastatin	134523-03-8	TWA	0.05 mg/m ³ (OEB 3)	Internal
		Wipe limit	0.5 mg/100 cm ²	Internal

Engineering measures : All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.
 Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices).
 Minimize open handling.

Personal protective equipment

Respiratory protection : General and local exhaust ventilation is recommended to maintain vapor exposures below recommended limits. Where concentrations are above recommended limits or are unknown, appropriate respiratory protection should be worn. Follow OSHA respirator regulations (29 CFR 1910.134) and use NIOSH/MSHA approved respirators. Protection provided by air purifying respirators against exposure to any hazardous chemical is limited. Use a positive pressure air supplied respirator if there is any potential for uncontrolled release, exposure levels are unknown, or any other circumstance where air purifying respirators may not provide adequate protection.

Atorvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/24/2019
6.1	09/13/2019	184708-00009	Date of first issue: 06/17/2015

Hand protection

Material : Chemical-resistant gloves

Remarks
Eye protection: Consider double gloving.
: Wear safety glasses with side shields or goggles.
If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.
Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Skin and body protection

: Work uniform or laboratory coat.
Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces.
Use appropriate degowning techniques to remove potentially contaminated clothing.

Hygiene measures

: If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.
When using do not eat, drink or smoke.
Wash contaminated clothing before re-use.
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance : granular

Color : No data available

Odor : No data available

Odor Threshold : No data available

pH : No data available

Melting point/freezing point : No data available

Initial boiling point and boiling range : No data available

Flash point : No data available

Evaporation rate : No data available

Flammability (solid, gas) : May form explosive dust-air mixture during processing, handling or other means.

Flammability (liquids) : No data available

Upper explosion limit / Upper : No data available

Atorvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/24/2019
6.1	09/13/2019	184708-00009	Date of first issue: 06/17/2015

flammability limit

Lower explosion limit / Lower flammability limit : No data available

Vapor pressure : No data available

Relative vapor density : No data available

Density : No data available

Solubility(ies)
Water solubility : No data available

Partition coefficient: n-octanol/water : No data available

Autoignition temperature : No data available

Decomposition temperature : No data available

Viscosity
Viscosity, kinematic : No data available

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Molecular weight : No data available

Particle size : No data available

SECTION 10. STABILITY AND REACTIVITY

Reactivity : Not classified as a reactivity hazard.

Chemical stability : Stable under normal conditions.

Possibility of hazardous reactions : May form explosive dust-air mixture during processing, handling or other means.
Can react with strong oxidizing agents.

Conditions to avoid : Heat, flames and sparks.
Avoid dust formation.

Incompatible materials : Oxidizing agents

Hazardous decomposition products : No hazardous decomposition products are known.

SECTION 11. TOXICOLOGICAL INFORMATION**Information on likely routes of exposure**

Inhalation
Skin contact
Ingestion
Eye contact

Atorvastatin Formulation

Version 6.1 Revision Date: 09/13/2019 SDS Number: 184708-00009 Date of last issue: 04/24/2019
Date of first issue: 06/17/2015

Acute toxicity

Not classified based on available information.

Components:**Calcium carbonate:**

- Acute oral toxicity : LD50 (Rat): > 2,000 mg/kg
Method: OECD Test Guideline 420
Assessment: The substance or mixture has no acute oral toxicity
- Acute inhalation toxicity : LC50 (Rat): > 3 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist
Method: OECD Test Guideline 403
Assessment: The substance or mixture has no acute inhalation toxicity
- Acute dermal toxicity : LD50 (Rat): > 2,000 mg/kg
Method: OECD Test Guideline 402
Assessment: The substance or mixture has no acute dermal toxicity

Cellulose:

- Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg
- Acute inhalation toxicity : LC50 (Rat): > 5.8 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist
- Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg

Atorvastatin:

- Acute oral toxicity : LD50 (Rat, male and female): > 5,000 mg/kg
LD50 (Mouse, male and female): > 5,000 mg/kg

Skin corrosion/irritation

Not classified based on available information.

Components:**Calcium carbonate:**

- Species : Rabbit
Method : OECD Test Guideline 404
Result : No skin irritation

Atorvastatin:

- Species : Rabbit
Result : No skin irritation

Atorvastatin Formulation

Version Revision Date: SDS Number: Date of last issue: 04/24/2019
6.1 09/13/2019 184708-00009 Date of first issue: 06/17/2015

Serious eye damage/eye irritation

Not classified based on available information.

Components:**Calcium carbonate:**

Species : Rabbit
Result : No eye irritation
Method : OECD Test Guideline 405

Atorvastatin:

Species : Rabbit
Result : No eye irritation
Method : Draize Test

Respiratory or skin sensitization**Skin sensitization**

Not classified based on available information.

Respiratory sensitization

Not classified based on available information.

Components:**Calcium carbonate:**

Test Type : Local lymph node assay (LLNA)
Routes of exposure : Skin contact
Species : Mouse
Method : OECD Test Guideline 429
Result : negative

Atorvastatin:

Test Type : Maximization Test
Routes of exposure : Skin contact
Species : Guinea pig
Result : negative

Germ cell mutagenicity

Not classified based on available information.

Components:**Calcium carbonate:**

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Method: OECD Test Guideline 471
Result: negative

Test Type: Chromosome aberration test in vitro
Method: OECD Test Guideline 473
Result: negative

Test Type: In vitro mammalian cell gene mutation test
Method: OECD Test Guideline 476

Atorvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/24/2019
6.1	09/13/2019	184708-00009	Date of first issue: 06/17/2015

Result: negative

Cellulose:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Test Type: In vitro mammalian cell gene mutation test
Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)
Species: Mouse
Application Route: Ingestion
Result: negative

Atorvastatin:

Genotoxicity in vitro : Test Type: reverse mutation assay
Test system: Salmonella typhimurium
Result: negative

Test Type: reverse mutation assay
Test system: Escherichia coli
Result: negative

Test Type: In vitro mammalian cell gene mutation test
Test system: Chinese hamster lung cells
Result: negative

Test Type: sister chromatid exchange assay
Test system: Chinese hamster lung cells
Result: negative

Genotoxicity in vivo : Test Type: In vivo micronucleus test
Species: Mouse
Cell type: Bone marrow
Application Route: Oral
Result: negative

Carcinogenicity

Not classified based on available information.

Components:

Cellulose:

Species : Rat
Application Route : Ingestion
Exposure time : 72 weeks
Result : negative

Atorvastatin:

Species : Mouse, male and female
Application Route : oral (gavage)

Atorvastatin Formulation

Version Revision Date: SDS Number: Date of last issue: 04/24/2019
6.1 09/13/2019 184708-00009 Date of first issue: 06/17/2015

Exposure time : 2 Years
NOAEL : 200 mg/kg body weight
LOAEL : 400 mg/kg body weight
Result : negative
Target Organs : Liver

Species : Rat, female
Application Route : oral (gavage)
Exposure time : 2 Years
LOAEL : 100 mg/kg body weight
Target Organs : Musculo-skeletal system

IARC No ingredient of this product present at levels greater than or equal to 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.

OSHA No component of this product present at levels greater than or equal to 0.1% is on OSHA's list of regulated carcinogens.

NTP No ingredient of this product present at levels greater than or equal to 0.1% is identified as a known or anticipated carcinogen by NTP.

Reproductive toxicity

Not classified based on available information.

Components:**Calcium carbonate:**

Effects on fertility : Test Type: Combined repeated dose toxicity study with the reproduction/developmental toxicity screening test
Species: Rat
Application Route: Ingestion
Method: OECD Test Guideline 422
Result: negative

Effects on fetal development : Test Type: Embryo-fetal development
Species: Rat
Application Route: Ingestion
Method: OECD Test Guideline 414
Result: negative

Cellulose:

Effects on fertility : Test Type: One-generation reproduction toxicity study
Species: Rat
Application Route: Ingestion
Result: negative

Effects on fetal development : Test Type: Fertility/early embryonic development
Species: Rat
Application Route: Ingestion
Result: negative

Atorvastatin:

Effects on fertility : Test Type: Fertility/early embryonic development

Atorvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/24/2019
6.1	09/13/2019	184708-00009	Date of first issue: 06/17/2015

Species: Rat, female
 Fertility: NOAEL: 225 mg/kg body weight
 Result: No effects on fertility.

Test Type: Fertility/early embryonic development
 Species: Rat, male
 Fertility: NOAEL: 175 mg/kg body weight
 Result: No effects on fertility.

Effects on fetal development : Species: Rat, female
 Developmental Toxicity: NOAEL: 20 mg/kg body weight
 Result: No teratogenic effects., Embryo-fetal toxicity.
 Remarks: Maternal toxicity observed.

Species: Rabbit, female
 Application Route: Oral
 Developmental Toxicity: NOAEL: 100 mg/kg body weight
 Result: No embryo-fetal toxicity.

STOT-single exposure

Not classified based on available information.

STOT-repeated exposure

May cause damage to organs (Liver, muscle) through prolonged or repeated exposure if swallowed.

Components:

Atorvastatin:

Routes of exposure : Ingestion
 Target Organs : Liver, muscle
 Assessment : May cause damage to organs through prolonged or repeated exposure.

Repeated dose toxicity

Components:

Calcium carbonate:

Species : Rat
 NOAEL : > 1,000 mg/kg
 Application Route : Ingestion
 Exposure time : 28 Days
 Method : OECD Test Guideline 422

Cellulose:

Species : Rat
 NOAEL : >= 9,000 mg/kg
 Application Route : Ingestion
 Exposure time : 90 Days

Atorvastatin:

Species : Rat, male and female

Atorvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/24/2019
6.1	09/13/2019	184708-00009	Date of first issue: 06/17/2015

LOAEL : 70 mg/kg
 Application Route : oral (gavage)
 Exposure time : 52 Weeks
 Target Organs : Liver

Species : Dog
 LOAEL : 10 mg/kg
 Application Route : oral (gavage)
 Exposure time : 104 Weeks
 Target Organs : Liver

Aspiration toxicity

Not classified based on available information.

Experience with human exposure

Components:

Atorvastatin:

Ingestion : Symptoms: muscle pain, Fatigue, stomach discomfort, Abdominal pain, constipation, flatulence, liver function change

SECTION 12. ECOLOGICAL INFORMATION

Ecotoxicity

Components:

Calcium carbonate:

Toxicity to fish : LL50 (Oncorhynchus mykiss (rainbow trout)): > 100 mg/l
 Exposure time: 96 h
 Test substance: Water Accommodated Fraction
 Method: OECD Test Guideline 203

Toxicity to daphnia and other aquatic invertebrates : EL50 (Daphnia magna (Water flea)): > 100 mg/l
 Exposure time: 48 h
 Test substance: Water Accommodated Fraction
 Method: OECD Test Guideline 202

Toxicity to algae/aquatic plants : NOELR (Pseudokirchneriella subcapitata (green algae)): 50 mg/l
 Exposure time: 72 h
 Test substance: Water Accommodated Fraction
 Method: OECD Test Guideline 201

EL50 (Pseudokirchneriella subcapitata (green algae)): > 100 mg/l
 Exposure time: 72 h
 Test substance: Water Accommodated Fraction
 Method: OECD Test Guideline 201

Toxicity to microorganisms : NOEC: 1,000 mg/l
 Exposure time: 3 h
 Method: OECD Test Guideline 209

Atorvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/24/2019
6.1	09/13/2019	184708-00009	Date of first issue: 06/17/2015

EC50: > 1,000 mg/l
 Exposure time: 3 h
 Method: OECD Test Guideline 209

Cellulose:

Toxicity to fish : LC50 (*Oryzias latipes* (Japanese medaka)): > 100 mg/l
 Exposure time: 48 h
 Remarks: Based on data from similar materials

Atorvastatin:

Toxicity to fish : LC50 (*Pimephales promelas* (fathead minnow)): > 92 mg/l
 Exposure time: 96 h
 Method: OECD Test Guideline 203

Toxicity to daphnia and other aquatic invertebrates : EC50 (*Daphnia magna* (Water flea)): 200 mg/l
 Exposure time: 48 h
 Method: OECD Test Guideline 202

Toxicity to algae/aquatic plants : EC50 (*Pseudokirchneriella subcapitata* (green algae)): 108 mg/l
 Exposure time: 72 h
 Method: OECD Test Guideline 201

NOEC (*Pseudokirchneriella subcapitata* (green algae)): 14 mg/l
 Exposure time: 72 h
 Method: OECD Test Guideline 201

Toxicity to fish (Chronic toxicity) : NOEC (*Pimephales promelas* (fathead minnow)): 0.49 mg/l
 Exposure time: 33 d
 Method: OECD Test Guideline 210

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC (*Daphnia magna* (Water flea)): 0.2 mg/l
 Exposure time: 21 d
 Method: OECD Test Guideline 211

Toxicity to microorganisms : EC50: > 1,000 mg/l
 Exposure time: 3 h
 Test Type: Respiration inhibition

Persistence and degradability

Components:

Cellulose:

Biodegradability : Result: Readily biodegradable.

Atorvastatin:

Biodegradability : Result: Not readily biodegradable.
 Biodegradation: 7.7 %
 Exposure time: 28 d
 Method: OECD Test Guideline 314

SAFETY DATA SHEET



Atorvastatin Formulation

Version Revision Date: SDS Number: Date of last issue: 04/24/2019
6.1 09/13/2019 184708-00009 Date of first issue: 06/17/2015

Bioaccumulative potential

Components:

Atorvastatin:

Partition coefficient: n-octanol/water : log Pow: 1.62

Mobility in soil

Components:

Atorvastatin:

Distribution among environmental compartments : log Koc: 2.84

Other adverse effects

No data available

SECTION 13. DISPOSAL CONSIDERATIONS

Disposal methods

Waste from residues : Dispose of in accordance with local regulations.
Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.

SECTION 14. TRANSPORT INFORMATION

International Regulations

UNRTDG

Not regulated as a dangerous good

IATA-DGR

Not regulated as a dangerous good

IMDG-Code

Not regulated as a dangerous good

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

Domestic regulation

49 CFR

Not regulated as a dangerous good

SECTION 15. REGULATORY INFORMATION

EPCRA - Emergency Planning and Community Right-to-Know

CERCLA Reportable Quantity

This material does not contain any components with a CERCLA RQ.

Atorvastatin Formulation

Version 6.1	Revision Date: 09/13/2019	SDS Number: 184708-00009	Date of last issue: 04/24/2019 Date of first issue: 06/17/2015
----------------	------------------------------	-----------------------------	---

SARA 304 Extremely Hazardous Substances Reportable Quantity

This material does not contain any components with a section 304 EHS RQ.

SARA 302 Extremely Hazardous Substances Threshold Planning Quantity

This material does not contain any components with a section 302 EHS TPQ.

SARA 311/312 Hazards : Combustible dust
Specific target organ toxicity (single or repeated exposure)

SARA 313 : This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.

US State Regulations

Pennsylvania Right To Know

Calcium carbonate	471-34-1
D-Glucose, 4-O-.beta.-D-galactopyranosyl-, monohydrate	64044-51-5
Cellulose	9004-34-6
Atorvastatin	134523-03-8
Croscarmellose sodium	74811-65-7

California Permissible Exposure Limits for Chemical Contaminants

Calcium carbonate	471-34-1
Cellulose	9004-34-6

The ingredients of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined


Atorvastatin Formulation

Version 6.1 Revision Date: 09/13/2019 SDS Number: 184708-00009 Date of last issue: 04/24/2019
 Date of first issue: 06/17/2015

SECTION 16. OTHER INFORMATION

Further information

NFPA 704:



HMIS® IV:

HEALTH	*	2
FLAMMABILITY		3
PHYSICAL HAZARD		0

HMIS® ratings are based on a 0-4 rating scale, with 0 representing minimal hazards or risks, and 4 representing significant hazards or risks. The "*" represents a chronic hazard, while the "/" represents the absence of a chronic hazard.

Full text of other abbreviations

ACGIH	:	USA. ACGIH Threshold Limit Values (TLV)
NIOSH REL	:	USA. NIOSH Recommended Exposure Limits
OSHA Z-1	:	USA. Occupational Exposure Limits (OSHA) - Table Z-1 Limits for Air Contaminants
ACGIH / TWA	:	8-hour, time-weighted average
NIOSH REL / TWA	:	Time-weighted average concentration for up to a 10-hour workday during a 40-hour workweek
OSHA Z-1 / TWA	:	8-hour time weighted average

AICS - Australian Inventory of Chemical Substances; ASTM - American Society for the Testing of Materials; bw - Body weight; CERCLA - Comprehensive Environmental Response, Compensation, and Liability Act; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DOT - Department of Transportation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; EHS - Extremely Hazardous Substance; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; HMIS - Hazardous Materials Identification System; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; MSHA - Mine Safety and Health Administration; n.o.s. - Not Otherwise Specified; NFPA - National Fire Protection Association; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic sub-

Atorvastatin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04/24/2019
6.1	09/13/2019	184708-00009	Date of first issue: 06/17/2015

stance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; RCRA - Resource Conservation and Recovery Act; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RQ - Reportable Quantity; SADT - Self-Accelerating Decomposition Temperature; SARA - Superfund Amendments and Reauthorization Act; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

Sources of key data used to compile the Material Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Revision Date : 09/13/2019

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

US / Z8